

Law360 Expert Analysis: Brian Trinque and Giulio DeConti on the Abilify Composition Patent Case

May 23, 2012

In an opinion that referred to a defendant's obviousness case for a small-molecule drug as "a poster child for impermissible hindsight reasoning," the U.S. Court of Appeals for the Federal Circuit affirmed a decision of the District Court for the District of New Jersey that upheld the validity of U.S. Patent No. 5,006,528, which provides composition of matter protection for the anti-psychotic agent Abilify (aripiprazole). Read more ...